Video Programs

For early relapsed myeloma, see how patient, disease, and prior therapy guide choices—and why teclistamab plus daratumumab shows standout PFS.

This segment addresses one of the most pressing challenges in advanced SCAC: management after progression on first-line carboplatin, paclitaxel, and retifanlimab.

In this segment focused on advanced renal cell carcinoma, Dr. Geynisman shifts the discussion to patients with intermediate and poor risk disease based on IMDC criteria and how this influences first-line treatment selection. Dr. McGregor and Dr. Wulff discuss how NCCN recommendations support both IO-IO and IO-TKI combinations in this population, while emphasizing that clinical context often guides the final decision.

In this introductory segment on advanced renal cell carcinoma, Dr. Wulff frames the challenge of selecting among multiple NCCN category 1 first-line regimens, including IO-IO and IO-TKI combinations. Dr. McGregor and Dr. Geynisman discuss how they approach treatment selection in clinical practice when several evidence-based options exist.

This segment addresses 2 key clinical questions following the adoption of chemo-immunotherapy in advanced SCAC: which patients benefit most and how long treatment should be continued.

Multiple myeloma care shifts to four-drug frontline regimens and MRD testing, boosting deep responses and guiding relapse strategies like BCMA CAR-T and genomic profiling.

Learn how to spot myeloma progression, distinguish relapse vs refractory disease, and decide when to treat—especially after lenalidomide maintenance and biochemical relapse.

This segment focuses on the durability of benefit with first-line chemo-immunotherapy in advanced SCAC and how the POD1UM-303 findings are shaping real-world treatment decisions.

Explore effective treatment strategies for managing functional tumors and their impact on patient quality of life, including systemic and liver-directed therapies.

Cabozantinib offers significant benefits for patients progressing on octreotide LAR, especially those with prior treatments and specific conditions.

In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, discusses the future of BPCDN treatment and how a collaborative care model should play a role in this rare disease.

In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, offers an overview of pivekimab sunirine and CD123-directed antibody-drug conjugates (ADCs) in the BPDCN pipeline.

The current research frontier in blastic plasmacytoid dendritic cell neoplasm (BPDCN) is moving toward combination triplet therapies. Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, explores the clinical rationale for triplet regimens combining tagraxofusp-erzs (Elzonris), azacitidine (Vidaza), and ventoclax (Venclexta).

In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, outlines monitoring parameters and intervention strategies required for patient safety following treatment with tagraxofusp for blastic plasmacytoid dendritic cell neoplasm (BPDCN).

BPDCN breakthroughs: CD123-targeting tagraxofusp and venetoclax-azacitidine combinations boost remissions, limit myelosuppression, and help reach transplant.

Spot BPDCN fast: skin-first clues, CD123/CD4/CD56 triad, mandatory CNS staging, and transplant-focused remission strategy.

Explore rising HPV-driven anal cancer burden and NCCN first-line choices, with trial data guiding chemo-immunotherapy patient selection.

Explore the NETTER-1 study's findings on PRRT for neuroendocrine tumors, including benefits, risks, and alternative treatments like everolimus.

NCCN updates recommend cabozantinib for neuroendocrine tumors, offering flexibility in treatment options for practitioners and patients.

NCCN updates recommend cabozantinib for neuroendocrine tumors, offering flexibility in treatment options based on patient needs and prior therapies.

Explore advanced treatment options for gastrointestinal neuroendocrine tumors, focusing on real-world case studies and emerging clinical data.

Leyla O. Shune, MD, looks to the future of treatment for patients with chronic graft-versus-host disease (cGVHD).

Explore innovative combination strategies for chronic GVHD treatment, focusing on emerging therapies and their potential to enhance patient outcomes.

Leyla O. Shune, MD, discusses sequencing agents in the in current treatment paradigm for chronic graft-versus-host disease, given the multitude of available FDA-approved agents and additional treatments emerging on the horizon.

Explore the complexities of interpreting clinical trial results versus real-world experiences in chronic GVHD treatment options.

Explore effective third-line treatments for chronic GVHD, focusing on the latest FDA-approved therapies and their impact on patient outcomes.

This segment examines optimal care for patients with early-stage non–small cell lung cancer (NSCLC) relying on coordinated multidisciplinary collaboration.

This case examines effective management of early-stage non–small cell lung cancer (NSCLC) requiring integrating imaging, laboratory results, and molecular profiling to guide therapy.